Several other brokerages also recently commented on CYTX. Zacks Investment Research downgraded Cytori Therapeutics from a hold rating to a sell rating in a research note on Thursday, November 9th. ValuEngine upgraded Cytori Therapeutics from a strong sell rating to a sell rating in a research note on Friday, February 2nd. Finally, B. Riley restated a hold rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th.
Shares of Cytori Therapeutics (NASDAQ:CYTX) opened at $0.32 on Tuesday. The company has a market capitalization of $11.10, a PE ratio of -0.36 and a beta of 3.56. Cytori Therapeutics has a 12 month low of $0.22 and a 12 month high of $2.08.
In related news, major shareholder Ag Postfinance sold 286,982 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $0.31, for a total value of $88,964.42. Following the transaction, the insider now owns 5,118,627 shares of the company’s stock, valued at approximately $1,586,774.37. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total transaction of $38,000.00. Following the completion of the transaction, the insider now directly owns 5,496,655 shares in the company, valued at approximately $2,088,728.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 695,767 shares of company stock worth $231,951. 1.90% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Perkins Capital Management Inc. lifted its position in Cytori Therapeutics by 134.0% in the 4th quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock valued at $644,000 after acquiring an additional 1,223,046 shares in the last quarter. Sabby Management LLC lifted its position in Cytori Therapeutics by 28.0% in the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after acquiring an additional 355,504 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Cytori Therapeutics by 81.9% in the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after acquiring an additional 275,653 shares in the last quarter. 10.82% of the stock is currently owned by institutional investors and hedge funds.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.